JPWO2020111018A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020111018A5 JPWO2020111018A5 JP2020557713A JP2020557713A JPWO2020111018A5 JP WO2020111018 A5 JPWO2020111018 A5 JP WO2020111018A5 JP 2020557713 A JP2020557713 A JP 2020557713A JP 2020557713 A JP2020557713 A JP 2020557713A JP WO2020111018 A5 JPWO2020111018 A5 JP WO2020111018A5
- Authority
- JP
- Japan
- Prior art keywords
- administered
- dose
- administration
- over
- agent according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003795 chemical substances by application Substances 0.000 claims 29
- 238000002560 therapeutic procedure Methods 0.000 claims 23
- PJZDLZXMGBOJRF-CXOZILEQSA-L folfirinox Chemical compound [Pt+4].[O-]C(=O)C([O-])=O.[NH-][C@H]1CCCC[C@@H]1[NH-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 PJZDLZXMGBOJRF-CXOZILEQSA-L 0.000 claims 19
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 16
- 229960002949 fluorouracil Drugs 0.000 claims 16
- KVUAALJSMIVURS-QNTKWALQSA-L calcium;(2s)-2-[[4-[[(6s)-2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]pentanedioate Chemical compound [Ca+2].C([C@@H]1N(C=O)C=2C(=O)N=C(NC=2NC1)N)NC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-QNTKWALQSA-L 0.000 claims 12
- 238000001990 intravenous administration Methods 0.000 claims 12
- 229960003301 nivolumab Drugs 0.000 claims 12
- 229960000779 irinotecan hydrochloride Drugs 0.000 claims 11
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 claims 11
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 10
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 10
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 10
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 10
- 229960001756 oxaliplatin Drugs 0.000 claims 10
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 10
- 230000000694 effects Effects 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 6
- 201000002528 pancreatic cancer Diseases 0.000 claims 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 6
- 230000001629 suppression Effects 0.000 claims 5
- 206010027476 Metastases Diseases 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 229940041181 antineoplastic drug Drugs 0.000 claims 4
- 230000009401 metastasis Effects 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 3
- 230000037396 body weight Effects 0.000 claims 3
- 230000004580 weight loss Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 201000009036 biliary tract cancer Diseases 0.000 claims 1
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 1
- 229950007712 camrelizumab Drugs 0.000 claims 1
- 229940121420 cemiplimab Drugs 0.000 claims 1
- 229940121432 dostarlimab Drugs 0.000 claims 1
- 206010022498 insulinoma Diseases 0.000 claims 1
- 208000022669 mucinous neoplasm Diseases 0.000 claims 1
- 208000021255 pancreatic insulinoma Diseases 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 229940121497 sintilimab Drugs 0.000 claims 1
- 229950007213 spartalizumab Drugs 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 claims 1
- 229950007123 tislelizumab Drugs 0.000 claims 1
- 229940121514 toripalimab Drugs 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018220866 | 2018-11-27 | ||
| JP2018220866 | 2018-11-27 | ||
| PCT/JP2019/046048 WO2020111018A1 (ja) | 2018-11-27 | 2019-11-26 | 免疫チェックポイント阻害薬およびｆｏｌｆｉｒｉｎｏｘ療法との併用によるがん治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2020111018A1 JPWO2020111018A1 (ja) | 2021-10-21 |
| JPWO2020111018A5 true JPWO2020111018A5 (enExample) | 2023-06-14 |
| JP7491220B2 JP7491220B2 (ja) | 2024-05-28 |
Family
ID=70853502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020557713A Active JP7491220B2 (ja) | 2018-11-27 | 2019-11-26 | 免疫チェックポイント阻害薬およびｆｏｌｆｉｒｉｎｏｘ療法との併用によるがん治療 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12447150B2 (enExample) |
| EP (1) | EP3888648A4 (enExample) |
| JP (1) | JP7491220B2 (enExample) |
| TW (1) | TWI818120B (enExample) |
| WO (1) | WO2020111018A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2720160T3 (es) * | 2005-05-09 | 2019-07-18 | Ono Pharmaceutical Co | Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas |
| IL298946A (en) * | 2020-06-18 | 2023-02-01 | Genentech Inc | Treatment with anti-tigit antibodies and pd-1 axis binding antagonists |
| EP4245301A4 (en) * | 2020-11-13 | 2024-08-21 | ONO Pharmaceutical Co., Ltd. | TREATMENT OF CANCER BY COMBINED USE OF AN EP4 ANTAGONIST AND AN IMMUNE CHECKPOINT INHIBITOR |
| WO2022200498A1 (en) * | 2021-03-26 | 2022-09-29 | BioNTech SE | Combination therapy with an anti-ca19-9 antibody and folfirinox in the treatment of cancer |
| CA3222362A1 (en) * | 2021-06-10 | 2022-12-15 | Ono Pharmaceutical Co., Ltd. | Cancer treatment method by combined use of cd47 inhibitory substance, immune checkpoint inhibitory substance, and standard therapy |
| EP4376809A4 (en) * | 2021-07-29 | 2025-06-04 | Topalliance Biosciences Inc. | PHARMACEUTICAL COMPOSITION OF ANTI-PD-1 ANTIBODY AND ITS USE |
| CA3235778A1 (en) * | 2021-10-20 | 2023-04-27 | Omid Veiseh | Methods of use and administration of encapsulated cells |
| WO2025151396A1 (en) * | 2024-01-08 | 2025-07-17 | Hoth Therapeutics, Inc. | Use of aprepitant for relieving side effects associated with the administration of weight loss medications |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| ES2720160T3 (es) | 2005-05-09 | 2019-07-18 | Ono Pharmaceutical Co | Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas |
| EA019344B1 (ru) | 2005-07-01 | 2014-03-31 | МЕДАРЕКС, Эл.Эл.Си. | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения |
| JP5191537B2 (ja) | 2007-06-18 | 2013-05-08 | エム・エス・ディー・オス・ベー・フェー | ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体 |
| CA3057687A1 (en) * | 2017-03-31 | 2018-10-04 | Five Prime Therapeutics, Inc. | Combination therapy for cancer using anti-gitr antibodies |
| WO2019139583A1 (en) * | 2018-01-10 | 2019-07-18 | Lee Patrice A | Methods and combination therapy to treat cancer |
-
2019
- 2019-11-26 US US17/297,339 patent/US12447150B2/en active Active
- 2019-11-26 TW TW108142901A patent/TWI818120B/zh active
- 2019-11-26 EP EP19891006.9A patent/EP3888648A4/en active Pending
- 2019-11-26 WO PCT/JP2019/046048 patent/WO2020111018A1/ja not_active Ceased
- 2019-11-26 JP JP2020557713A patent/JP7491220B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020111018A5 (enExample) | ||
| JP7491220B2 (ja) | 免疫チェックポイント阻害薬およびｆｏｌｆｉｒｉｎｏｘ療法との併用によるがん治療 | |
| JP2017533912A5 (enExample) | ||
| RU2016148927A (ru) | Лечение рака легкого с помощью комбинации антитела против pd-1 и другого противоракового средства | |
| JP2019530752A (ja) | がんを治療するための薬物の調製における、抗ｐｄ‐１抗体とｖｅｇｆｒ阻害剤とを組み合わせた使用 | |
| JP2016530280A5 (enExample) | ||
| JP2017031160A5 (enExample) | ||
| JP2011088921A (ja) | 血管形成及び／又は増加した血管透過性に関連する疾病の治療におけるゲムシタビンと、そして場合により電離放射と組み合わせたキナゾリン誘導体ｚｄ６４７４の使用 | |
| FI3463345T3 (fi) | Farmaseuttisia yhdistelmiä | |
| JP2019526595A5 (enExample) | ||
| JP2019510785A5 (enExample) | ||
| Kubicek et al. | Phase I trial using the proteasome inhibitor bortezomib and concurrent chemoradiotherapy for head-and-neck malignancies | |
| JP2020517696A5 (enExample) | ||
| JP2015525798A5 (enExample) | ||
| JP2020530467A5 (enExample) | ||
| JP2019508476A5 (enExample) | ||
| JP2017503846A5 (enExample) | ||
| JPWO2022269525A5 (enExample) | ||
| 938P KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) in combination with lenvatinib in the treatment for advanced unresectable or metastatic hepatocellular carcinoma (HCC): preliminary efficacy and safety results of a prospective phase II trial | ||
| Novello et al. | Motesanib plus carboplatin/paclitaxel in patients with advanced squamous non–small-cell lung cancer: results from the randomized controlled MONET1 study | |
| JP2019534251A5 (enExample) | ||
| Sun et al. | Phase II study of S-1 plus cisplatin as first-line therapy in patients with metastatic esophageal carcinoma | |
| Hahn et al. | Metronomic oral paclitaxel shows anti-tumor effects in an orthotopic mouse model of ovarian cancer | |
| JPWO2022260132A5 (enExample) | ||
| JP2024174997A (ja) | Ｃｄ４７阻害物質、免疫チェックポイント阻害物質および標準療法の併用によるがん治療法 |